
    
      This is a prospective, multi-center, open-label study involving subjects with proven or
      probable coccidioidomycosis refractory to fluconazole therapy following >40 days of treatment
      or subjects with proven or probable coccidioidomycosis who are intolerant to fluconazole.

      The availability "Super Bioavailability" (SUBA) itraconazole 65 mg capsules with twice-daily
      dosing options with improved pharmacokinetics and lack of food or acidity requirements offers
      a substantial opportunity to improve the treatment of subjects with coccidioidomycosis.
    
  